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Abstract Patients ask for procedures with long-lasting
effects. ArteFill is the ﬁrst permanent injectable approved in
2006 by the FDA for nasolabial folds. It consists of cleaned
microspheres of polymethylmethacrylate (PMMA) sus-
pended in bovine collagen. Over the development period of
20 years most of its side effects have been eliminated to
achieve the same safety standard as today’s hyaluronic acid
products. A 5-year follow-up study in U.S. clinical trial
patients has shown the same wrinkle improvement as seen
at 6 months. Long-term follow-up in European Artecoll
patients has shown successful wrinkle correction lasting up
to 15 years. A wide variety of off-label indications and
applications have been developed that help the physician
meet the individual needs of his/her patients. Serious
complications after ArteFill injections, such as granuloma
formation, have not been reported due to the reduction of
PMMA microspheres smaller than 20 lm to less than 1%
‘‘by the number.’’ Minor technique-related side effects,
however, may occur during the initial learning curve.
Patient and physician satisfaction with ArteFill has been
shown to be greater than 90%.
Keywords ArteFill  Dermal ﬁller  Permanent ﬁller 
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Introduction
The mechanism of action of ArteFill
  (Suneva Medical,
San Diego, CA) and its injection techniques have been
described and discussed in detail in the companion article
[1]. ArteFill is the product of 25 years of development and
experience with human implantation of its predecessors,
which have yielded valuable lessons, especially how to
improve the manufacturing process and to prevent adverse
events [2]. ArteFill was approved by the FDA in October
2006 speciﬁcally for the correction of nasolabial folds [3].
Subsequent clinical experience with more than 15,000
treated patients has conﬁrmed an extremely low incidence
of adverse events—none of them serious. At present, there
are no other FDA-approved indications, and the manufac-
turer does not support or promote additional indications
without the demonstrated efﬁcacy studies and FDA-
approved expanded labeling. However, physicians are
independently able to use medical products as they see ﬁt
for the beneﬁt of their patients [4]. The authors have
extensive experience in expanded uses of ArteFill in the
management of soft tissue contour deformities and deﬁ-
ciencies. Their clinical experience is summarized herein.
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2. There is ease of injection due to a funnel in the syringe,
despite a viscosity three times that of collagen injec-
tions alone.
3. Aesthetic correction with ArteFill appears to be sus-
tained formanyyearsbecausethePMMAmicrospheres
cannot be broken down by enzymes or removed by
phagocytosis.
4. Biocompatibility, safety, and stability at the implanta-
tion site persist indeﬁnitely.
5. Maintenance of volume and pliability appear to be a
product of natural and continuous connective tissue
turnover and collagen deposition.
6. No migration, dislocation, or erosion through the skin
has resulted, coincident with the complete encapsula-
tion of the PMMA components [5].
7. There is minimal foreign body reaction as a result of
the smooth surface of the microspheres and their
uniform size.
Candidates for Treatment
The best candidates for treatment with ArteFill appear to be
patients with well-deﬁned wrinkle lines and furrows and
little excess skin. If a patient is unsure about accepting the
permanence of ArteFill treatment or desires to ‘‘preview’’
the expected effect, an initial implantation of a hyaluronic
acid ﬁller may serve to ensure that the patient will accept
the ‘‘permanent’’ ArteFill result.
Patients with sebaceous skin and large pores but few
deep folds are ideal candidates and should achieve good
and long-lasting results, whereas patients with extremely
thin and loose skin are poor candidates for ArteFill. In
these thin-skinned patients the ArteFill implants may be
palpable, show through with tension on the skin, or even be
visible. Interestingly, the thickness of the facial dermis is
not usually diminished in older patients as is commonly
expected because of the well-known thinning of the dermis
of the extremities; the facial dermis gets thicker with age
[6], as does the size of the nose, ears, and chin.
Indications
Nasolabial Folds
Nasolabial creases are best supported by two to three bands
of ArteFill implanted parallel and strictly medial to the fold
(Fig. 1). ArteFill is still a viscous paste during the ﬁrst
3 days after implantation and may be moved laterally by
facial muscle movement. Care must be taken not to implant
too superﬁcially, i.e., intradermal, to prevent ridge forma-
tion. The subalar triangle should be leveled by fanlike
injections (Figs. 1 and 2). If injected intradermally, the
implant site may appear erythematous for several months
and the implant may be visible in the form of little granules
(Fig. 3). To avoid this technical error, strict implantation of
ArteFill along the dermal-subdermal junction is essential
[1, 4]. A second implantation is often necessary, especially
in the lower third of the nasolabial crease adjacent to the
corner of the mouth. Depending on the activity of facial
Fig. 1 The nasolabial fold can be divided in three regions: The upper
subnasal triangle must be treated with a fanning technique. The
corners of the mouth and marionette lines are treated with a
superﬁcial criss-crossing technique ([2] with permission from
Elsevier)
Fig. 2 Injections beneath a deep nasolabial fold have to be repeated
at 4-week intervals until leveling is achieved ([2] with permission
from Elsevier)
274 Aesth Plast Surg (2010) 34:273–286
123muscle movement, the result may last for many years [3, 7]
(Figs. 4, 5, 6, and 7).
Horizontal Forehead Lines
Transverse rhytids respond well to treatment. The gray of
the needle should not show through the wrinkle line during
injection. Superﬁcial intradermal implantation may result
in the formation of small granules like a string of pearls (as
seen in Fig. 3) within the line. For deeper wrinkle lines, a
second and third session will often be required.
Glabellar Frown Lines
Glabellar lines generally pose little problem for ArteFill
treatment since the dermis is thick and the connective
Fig. 3 A ridge may result after partial intradermal injection. This is
the most frequent technical mistake made during the initial learning
curve. This ridge can be leveled easily by dermabrasion or shaving
with a surgical blade
Fig. 4 Deep nasolabial fold in a patient with thick sebaceous skin, an
ideal indication for ArteFill ([2] with permission from Elsevier)
Fig. 5 After two sessions with 1.7 ml of Artecoll in each fold ([2]
with permission from Elsevier)
Fig. 6 Each nasolabial fold was augmented with 1.7 ml of Arteplast
in 1991
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123tissue beneath provides good support for the implant. When
slight overcorrection is deemed necessary, care must be
taken not to inject too far inferiorly, otherwise a nodule
may appear. Deep lines and furrows may require repeated
treatments. They can often be placed intradermally because
of the thickness of the skin in this area. During the 20-year
history of Artecoll use in Europe, no case of glabellar skin
necrosis [8–10] or vision loss [11] was reported to the
manufacturer. Unlike collagen and hyaluronic acid, Arte-
Fill cannot be injected through a resting needle; the needle
has to be moved back and forth while avoiding intravas-
cular deposition. In severe cases of glabellar frown lines,
Botox
  can be administered along with ArteFill to
accomplish full correction and aid the ArteFill effect.
Shadowed Lower Lids
In a dark ring along the nasojugular groove or marginal
arcus, the thin skin together with the orbicularis occuli
muscle must be lifted from the infraorbital rim with a solid
implant [12] or with a band of ArteFill of 2–3 cm long
(Figs. 8 and 9). The implantation has to be strictly epipe-
riosteal, i.e., beneath the orbicularis occuli muscle and just
superﬁcial to the insertion of the orbital septum [13, 14].
The bone must be felt with the tip of the needle. Retracting
the needle slightly, ArteFill can be spread along the lower
orbital rim. Care must be taken to withdraw the needle
without pressure since implantation into the muscle will
cause a nodule, which may have to be excised. Age-related
or postsurgical lower-lid ectropium may effectively be
treated with an injection of hyaluronic acid [15] or per-
manently with ArteFill.
Crow’s Feet Wrinkles
ArteFill is indicated in the lateral periocular area only if
there are a few deep crow’s feet in a patient with thick skin.
Treatment of multiple crow’s feet with ArteFill in patients
with thin and ﬂaccid skin is contraindicated because the
implant may show through and appear as ﬁne granules.
Facial Wasting and Cheek Depressions
Certain patients may develop a depression or hollowing of
the cheeks in front of the canine fossa [16] or in the sub-
malar region. This circumscribed atrophy of the malar fat
pad and adjacent subcutaneous fat is pronounced in
patients with facial lipodystrophy who are on HIV medi-
cation [17, 18]. Subdermal implantation of ArteFill in mild
cases, or epiperiosteal implantation [14] in severe cases,
may be of great beneﬁt (Figs. 10 and 11). In severe cases
grade 3 or 4, silicone implants [12, 16, 18, 19] can be
inserted before a ﬁller [20] is applied.
Fig. 8 Shadowed lower eyelids can be raised by a strand of ArteFill
augmenting the lower bony orbital rim
Fig. 9 Result 10 years after 0.8 cc of ArteFill delivered epiperiost-
eally beneath the orbicularis occuli muscle on each side
Fig. 7 The same woman as in Fig. 6 at age 60: a lasting result
15 years after Arteplast injections
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123Acne Scars
ArteFill appears to be very effective for mature, mildly
depressed ‘‘rolling’’ acne scars [21]. These can be ﬁlled
either horizontally from a distance of 5–10 mm (Fig. 12)o r
in ‘‘boxcar scars’’ with the aid of a microdroplet delivery
device perpendicular downward directly into the center,
continuously guiding the needle back and forth. Fresh,
immature scars should not be treated because they may not
show improvement and may worsen. So-called ‘‘ice-pick’’
acne scars require pretreatment since injection of any ﬁller
may cause a ‘‘donut’’ effect. They should be punched and
sutured or subcised with a No. 11 blade or a double-
beveled Nokar needle at about 1-mm depth. The fresh
wound cavity can easily be ﬁlled with ArteFill 3–8 days
later, after the swelling has subsided and the incision has
healed.
Traumatic Scars
If surgical or traumatic scars are mature, depressed, and
soft, they can easily be ﬁlled with ArteFill in a three-
dimensional fanlike manner using the tunneling technique.
A second implantation may be necessary 3 months later.
Depressed scars are among the most effective indications.
Irregularities of the Nose
Irregularities of the nose, especially after rhinoplasty or
collapsed nostrils, can be improved quite easily by deep
epiperiosteal or epichondral placement of ArteFill [20, 22].
The ‘‘saddle nose’’ deformity and sunken bridge of an
Fig. 10 Facial wasting is a common side effect of HAART therapy in
HIV-positive patients (courtesy of Dr. G. Pierone)
Fig. 11 The hollowed cheeks can be ﬁlled successfully with ArteFill
through a blunt microcannula (courtesy of Dr. G. Pierone)
Fig. 12 Top Patient with acne received 1.6 ml of ArteFill in her skin
depressions on both temples and zygomatic arches. Bottom Six
months after treatment. Acne scars need repeated intradermal (!)
treatments
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123oriental nose can be raised by administering 0.4–0.8 cc of
ArteFill. A tape splint should keep the implant aligned, but
straightening the implant during the following 3 days is
possible if asymmetry should occur during sleep or there is
some other accidental displacement. In patients with an
acute nasolabial angle, it has been helpful to implant a
deposit of ArteFill subdermally at the columellar base
(Figs. 13 and 14) and the nasal tip. In order to prevent
ﬂattening, a double silicone nostril stent (as used in cleft lip
surgery) can be applied for 1 week.
Lip Enhancement
Lip enhancement is the most demanding of applications
because of the potential for nodule formation. However,
applying the correct technique, it has proved to be one of
the most rewarding indications for ArteFill (Figs. 15 and
16). There appears to be a natural plane between the white
roll and the orbicularis oris muscle (Figs. 17 and 18),
which may be ﬁlled. An anesthetic cream [23]o ra n
anesthetic ﬁeld block in the labiogingival folds for the
augmentation of the upper and lower lips provides comfort
for the patient during the procedure [24]. One can then
direct the needle coming from the lateral aspect into the
correct plane (Fig. 18).
While injecting, it is useful to hold the white roll
between two ﬁngers to prevent dislocation. Usually half of
the lip can be implanted by withdrawing the needle while
injecting under pressure (Fig. 18). A volume of 0.4–0.8 cc
ArteFill should be sufﬁcient for each lip. A larger volume
may result in a dense mass and pain, so one must take care
to augment the lips in stages. If ArteFill is well tolerated
Fig. 13 In a Mexican nose, the drooping tip or negative nasolabial
angle can be lifted by one injection of ArteFill
Fig. 14 Same patient as in Fig. 13. One syringe of ArteFill has
been injected between the anterior nasal spine and the base of the
columellar cartilages
Fig. 15 Thin upper lip after ineffective surgical lip lift (bullhorn
excision)
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123and the lips are soft after 3 months, more ArteFill can be
added to the same tissue plane.
A second implantation of ArteFill applied horizontally
along the dry–wet border (red line) of the inner vermilion
increases fullness or the ‘‘pouting’’ effect (Fig. 17). At this
location the serial puncture technique must be used
exclusively to prevent clumping of ArteFill during early lip
movement (Fig. 18).
ArteFill should never be implanted into the orbicularis
oris muscle since this may cause dislocation and nodule
formation (Fig. 19). The patient must be aware that sub-
mucosally implanted ArteFill can nearly always be felt
with the tongue or the teeth and may appear white when the
lip is stretched. Sensitivity to touch and kissing may last up
to 1 year but usually resolves spontaneously.
A ﬂattened philtrum [25] may be raised effectively with
two vertical injections of ArteFill starting from below, i.e.,
from the two peaks of the Cupid’s bow within the white
roll. Very rarely has an implant dislodged into the sur-
rounding tissue. In such an unlikely event, correction is
possible by molding the implant between two ﬁngers into
the philtrum or the white roll. The injections should be
Fig. 16 Same patient as in Fig. 15 after augmentation of upper and
lower lips with 1.2 cc of Artecoll in each
Fig. 17 Never inject a ﬁller into muscles but rather into the natural
pockets beneath the ‘‘white roll’’ in front or the ‘‘red line’’ in the back
of the lip
Fig. 18 Injecting one strand of ArteFill into the white roll enhances
the pouting effect. In lip augmentation, the submucosal ‘‘serial
puncture technique’’ along the dry–wet border is the treatment of
choice for the prevention of lumps
Fig. 19 Lumps in the vermilion may occur when early muscle
movement compresses material into a ball when mistakenly injected
into the muscle into a ball
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123done using linear threading and under no circumstances
should the serial puncture technique be used in the visible
part of the lip.
Avoid injecting ArteFill into an upper lip that has
excessive vertical height (as in Figs. 6 and 7), since this
may further lengthen the lip and further hide the front teeth
when smiling [25].
Residual postsurgical cleft lip irregularities often
respond well to ArteFill implantation, especially for
improvement of the deﬁcient or absent white roll and
philtrum (Figs. 20 and 21). ArteFill is not indicated for
larger defects of the vermilion, such as a whistle deformity,
because the implant may be too ﬁrm in such circumstance.
Unpleasant Smile
One patient disliked her ‘‘gummy smile’’ so much that she
kept a mass of chewing gum in her upper labiogingival
sulcus to diminish gum exposure. The same effect may be
achieved permanently with 1–2 ml ArteFill placed epipe-
riosteally in a horizontal direction in front of the roots of
the upper incisors (Figs. 22, 23, and 24).
Perioral Lip Lines
Radial upper-lip lines usually extend from tiny notches in
the vermilion border, which cause the lip to appear aged
and lipstick to track and smudge. In younger patients with
good projection of the white roll, these wrinkles can be
treated vertically from above. It has been helpful to inject
one unit of botulinum toxin into each radial lip line
2 weeks before ArteFill treatment. This pretreatment pre-
vents pouting for several weeks. In patients with more than
four lines, a better result seems to be achieved by injecting
transversely across the entire white roll (Fig. 18). This
Fig. 20 Patients after cleft lip surgery often lack pouting and
philtrum
Fig. 21 Philtrum and vermilion border were augmented with 0.4 cc
of ArteFill
Fig. 22 Unpleasant smile is caused by a missing anterior nasal spine
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123often prevents further wrinkling and causes the disap-
pearance of the lower half of ﬁne radial lip lines (Fig. 25).
A piece of horizontal tape should be worn for 2–3 days to
prevent pouting, otherwise nodules may be produced
(Fig. 26).
Additional augmentation of the lost philtrum from
below may give the lip a more youthful look [25]. Patients
must be advised that their treated folds will improve over
time. In recurrences, a second implantation between the
ArteFill ‘‘base’’ and the dermis of the wrinkles usually
provides a lasting effect. Patients should be informed that
ArteFill can sometimes be felt as a rubber-like substance or
Fig. 23 Augmenting the anterior maxilla behind the labiogingival
fold will prevent ‘‘gummy smile’’
Fig. 24 The ‘‘gummy smile’’ is gone because the lip is partly blocked
when pulled upward
Fig. 25 Treating radial lip
lines: Their lower half will
disappear after simple injection
of a horizontal strand into the
‘‘empty pocket’’ beneath the
vermilion border. The upper
half is treated with vertical
strands
Fig. 26 Lumps in the lip developed because the patient smoked
immediately after injection. Intralesional steroids diminished the
lumps by 50%
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123eventually may be seen as a white substance in the lips
when the skin is stretched.
Negative Corners of the Mouth
These may be the most difﬁcult problems to treat but can
be very rewarding areas for ArteFill implantation. Success
has been achieved with a steplike approach. First, the lower
white roll is augmented horizontally about 1 cm from the
corner. Then, four to ﬁve vertical and horizontal threads of
ArteFill are be placed absolutely subdermal (Fig. 1) using a
cross-hatching technique since there is often a lack of
subcutaneous fat. This supports this area and slightly lifts
the corner of the mouth. It may be helpful to extend some
of the implant around the upper lip in a C-shaped fashion.
Be aware that if the skin is relatively thin, implanting
ArteFill superﬁcially may result in telangectasia. Avoid the
orbicularis oris muscle (Fig. 17). Best results have occur-
red with ArteFill implanted in many different tunnels and
always in two or more sessions.
Marionette Lines
The vertical elongation of the dystopic corners of the
mouth as they extend to the mandibular border has been
greatly improved by linear threading and deep intradermal
crisscross implantation of ArteFill (Fig. 1). There is little
subdermal fat between the skin and orbicularis oris muscle
in this location. Therefore, implantation of any ﬁller must
be very superﬁcial but still subdermal in order to avoid
lumping.
Horizontal Chin Fold
The skin in the area of the mentolabial fold is relatively
tight and this fold is relatively difﬁcult to treat with Arte-
Fill (Figs. 27 and 28) or any other dermal ﬁller product.
Therefore, most patients will need a second or third
implantation. There is a danger of nodule formation in the
fold if ArteFill is implanted too superﬁcially in the skin. If
this should occur, the ﬁne nodules can be removed by
dermabrasion.
Horizontal Neck Folds
The dermis of the neck is extremely thin. Therefore, a 2-
cm-long test implantation to avoid overcorrection is a good
idea. Implantation results are favorable in the young
patient, but a second treatment often is required (Figs. 29
and 30). An aged and ﬂaccid neck is a contraindication for
ArteFill. Patients with dark skin must know that underlying
hyperpigmentation in the folds can be more obvious after
augmentation.
Nipple Augmentation
Flat nipples and inverted nipples Grades I and II (i.e., those
that can be stimulated to protrude) and nipple volume
asymmetries can be augmented with 0.2–0.4 cc of ArteFill.
Fig. 27 A deep horizontal chin fold was augmented with 0.8 ml of
Artecoll in one session
Fig. 28 The same patient as in Fig. 27 eight years later
Fig. 29 Horizontal neck folds in a young patient
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123On applying deep local anesthesia beneath the nipple, the
desired amount of augmentation can be estimated by using
the anesthetic to temporarily ‘‘plump’’ the nipple. After
waiting 10 min until the anesthetic ﬂuid is absorbed, one
lifts the nipple with a small hook and implants ArteFill
from the side, moving the needle back and forth to avoid
implantation into the ducts. If some material extrudes into
the ducts, it can easily be removed by massage. To date,
there have been no reports of duct blockage by implanta-
tion of ArteFill. If treatment of inverted nipples Grades III
and IV is desired, ArteFill implantation without blind
severance of all ducts may increase the inversion. There-
fore, in severe grades of nipple inversion, the ducts should
ﬁrst be severed as deeply as possible while lifting the
inverted nipple with a hook. ArteFill may be implanted 3–
4 days later.
Hand Rejuvenation
Even for patients who have undergone successful facial
rejuvenation, atrophied and indented dorsal spaces between
the metacarpal bones is a sure manifestation of advanced
age. Mitigation of the appearance of aged hands has been
achieved successfully with Sculptra
  [26] and Radiesse
 
[27]. Experience with ArteFill suggests that a 1:1 dilution
with saline through a Luer-lock connector to a 2-cc syringe
creates easier ﬂow and provides good volume. A long blunt
23G cannula should be applied to the 2-cc syringe and
inserted between the knuckles. Fanlike injections of the
dilute ArteFill into the subcutaneous space will push the
veinsawayandﬁlltheindentations.Massageoftheareamay
be necessary to allow even distribution of the microspheres.
Most patients require two treatments 4 weeks apart.
Combined Treatments
Laser treatment is no contraindication for ArteFill. In fact,
it may be considered a complimentary treatment since
ArteFill and the laser affect different layers of the skin.
Laser peeling of the epidermis can be performed either 3–
6 months before or preferably immediately after ArteFill
implantation. Postinjection edema of the wrinkle lines and
furrows seems to enhance the efﬁcacy of the laser.
Dermabrasion and chemical peelings affect the same
relatively superﬁcial plane as laser resurfacing, i.e., the
epidermis and papillary dermis. Therefore, none of these
modalities should interfere with the implantation of Arte-
Fill, which is injected deeper (in the reticular dermis).
ArteFill can be injected either just before or weeks after the
resurfacing procedure.
Facelifts in general do not correct very pronounced
nasolabial folds or deep marionette lines. The treatment of
choice for nasolabial folds is often a midface lift, which
may produce scleral show in certain patients. Therefore,
deep nasolabial or labiomental creases can be augmented
with ArteFill just prior to a facelift, during the surgical
session, or at a later time.
Botulinum toxin creates temporary paralysis of certain
facial muscles but does not permanently eliminate deep
facial furrows or wrinkles. ArteFill appears to be an
excellent adjunct to Botox
  treatments. ArteFill can be
implanted concurrently or at a later time. In many instan-
ces, it appears that the long-term augmentation resulting
from ArteFill is enhanced by the paralyzing effect of Bo-
tox, which eliminates the motion in a particular wrinkle
line (e.g., glabellar frown lines) and therefore enhances the
results with ArteFill as the collagen remodels.
Complications
Errors of Technique
Because of its long-lasting effect, ArteFill demands a good
technique and does not favor those who fail to heed the
guidelines that are the product of long experience.
• Uneven distribution in the form of a string of pearls can
be compensated by a second implantation of ArteFill
into the gaps.
• The most common mistake resulting in incomplete or
inadequate treatment is placing the ArteFill too deep
(into the subcutaneous fat). The implantation must be
redone correctly.
• Implantation too superﬁcially may cause long-lasting
redness and itching, which can be treated with corticoste-
roidcreamorintradermalcorticosteroidinjections[28,29].
Fig. 30 Same patient as in Fig. 29 immediately after subdermal
injection of a total of 0.8 cc of ArteFill
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Ridges or intradermal nodules can occur a few weeks
following a too superﬁcial (intradermal) injection of Ar-
teFill (Fig. 3). Constant muscle movement appears to push
the intradermal implant to be more superﬁcial. Ridges or
superﬁcial nodularity can be easily removed by derm-
abrasion or tangential shaving without creating a noticeable
scar because ‘‘exposed’’ ArteFill implants will epithelialize
just like normal abraded skin. Dislodged nodules caused by
intramuscular implantation may be softened by intrale-
sional corticosteroid injections or, if palpable intraorally,
may be excised. Excision of a nodule should always be
performed thoroughly and completely since any residual
ArteFill may potentially cause secondary hypertrophic
scarring.
Hypertrophic Scarring
This phenomenon may occur in certain patients prone to
keloid formation (Asians and African Americans) after
superﬁcial implantation of ArteFill. The therapy of choice
is intralesional triamcinolone injections, which may level
but do not narrow the scar.
Long-Lasting Redness or Telangectasia
This occurrence is usually caused by dilated capillaries,
especially if extremely thin skin overlies the implant. This
can be treated and resolved by laser or Intense-Pulse-Light
(IPL) therapy [29].
Lumpiness in the Lip
Objectionable lip nodularity (Fig. 18) occurs frequently
after implanting strands of ArteFill or any other injectable
in the lip. Muscle movement during the ﬁrst few days
compresses the strands into nodules, which are best
removed surgically (stab incision) if obvious or disturbing.
They can be prevented by the serial puncture technique.
Early smoking may induce nodularity. One female patient
(Fig. 26) smoked immediately after implantation and
compressed the injected strands into nodules. An intrale-
sional injection of Kenalog
  4 weeks later, after the bovine
collagen was replaced by connective tissue, diminished the
volume by half and leveled the nodules.
Allergic Reactions
Allergic reactions to the polymerized acrylic in PMMA
microspheres are extraordinarily rare. However, as with all
collagen preparations, allergic reactions to ArteFill’s
collagen carrier may occur. Most of the allergenic te-
lopeptides have been enzymatically removed in the partly
denatured collagen of ArteFill. There were only two
positive skin tests (0.2%) in an ArteFill skin test study
involving 1000 patients; this result may allow removal of
the FDA-required skin test for ArteFill in the future.
Subsidence of the Implant
PMMA microspheres cannot be phagocytized by macro-
phages or giant cells and cannot be broken down by
enzymes. Therefore, the microspheres will remain perma-
nently beneath the crease. However, if injected too deeply
they will remain in the subcutaneous fat without effect on
the crease. It should also be noted that facial muscle
movement over several years may push the implant
somewhat deeper if it is already primarily in the subcuta-
neous fat, and the crease may reappear after 5–10 years. If
this occurs, another ArteFill implant on top of the previous
one is reasonable.
Granuloma Formation
With third-generation ArteFill, true granuloma formation is
a rare event and has not occurred to date in the more than
15,000 ArteFill patients treated in the U.S. The incidence
of granuloma formation with the second-generation prod-
uct Artecoll was 0.02% (1:5000), with manifestation from
6 months to 6 years after treatment [28, 30]. Granulomas
can develop after the injection of any dermal ﬁller at a rate
of 0.01–1.0% but can be treated effectively with intrale-
sional corticosteroid (Kenalog
 ) injections [31]. Granulo-
mas are an overreaction of the body’s cellular defense
system [30]. Therefore, surgical removal of true granulo-
mas [32] is the least one should consider since their borders
are not conﬁned and recurrences are almost predictable.
Treatment of Complications
Implant nodules, hypertrophic scarring, and misplaced
ArteFill (Figs. 3, 19, and 26) react well to intralesional
long-term crystalline corticosteroids [29]. Local steroids
inhibit ﬁbroblast activity and collagen deposition, macro-
phage activity, and giant cell formation, as well as swell-
ing, itching, and pain. A 1:1 mixture of lidocaine and
triamcinolone = ﬂuor-prednisolone (Kenalog
  or Volon-
A
 ) up to 20 mg/cc, or betamethasone (Diprosone
 )u pt o
5 mg/cc, can be injected safely through a 1-ml syringe with
a Luer-lock and a 30G needle. The steroid must be injected
strictly into the nodule while guiding the needle tip back
and forth. Corticosteroids injected into the surrounding soft
tissue, especially fat, may cause temporary or, rarely,
permanent skin atrophy. Should atrophy occur, a temporary
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123ﬁller such as hyaluronic acid will level the indentation until
natural recovery occurs, usually within 3–12 months [31].
Potential Adverse Events Not Yet Reported
As with any injection into the face, ArteFill may be inad-
vertently implanted into a blood vessel. Theoretically,
forceful injection into a dermal arterial branch of the
supratrochlear artery could cause retrograde movement of
the implant material into retinal arteries, resulting in vas-
cular occlusion. Such complications have been reported
with the use of collagen injections and, in rare cases, have
resulted in the sudden and permanent loss of vision. Similar
complications have been associated with other injectable
preparations, including Brazilian PMMA products [8–11,
33, 34], fat, corticosteroids, local anesthetics, and angio-
graphic agents, but have not been reported after injection of
Artecoll or ArteFill. These ﬁndings emphasize the impor-
tance of avoiding implantation into blood vessels by using
blunt cannulas or by moving a sharp needle back and forth
during implantation while maintaining constant pressure on
the plunger.
Discussion and Conclusion
During its ﬁrst two years of clinical use, ArteFill has
proved to be an extremely safe and predictable soft tissue
ﬁller. Granuloma incidence, a small but consistent problem
with its predecessor product, has been nil in the more than
15,000 patients treated (www.fda.gov/cdrh). Nevertheless,
ArteFill still requires a learning curve and technical proﬁ-
ciency because of its higher viscosity and longer persis-
tence [1, 35] than other available ﬁllers. As physicians’
skills improve with repeated use of ArteFill, conﬁdence
builds and consistently excellent results and patient satis-
faction emerge [3, 7, 36, 37].
Those who practice aesthetic surgery and dermatology
are fortunate to have many tools at their disposal, including
resurfacing modalities (lasers, dermabraders, chemicals),
advanced surgical approaches with adjunct devices, para-
lytic agents to instantly mitigate adverse muscle activity,
and dermal ﬁllers, and soft tissue augmentation injectables.
Until recently, however, there was no legally available
permanent ﬁller to place in the plastic surgeons’ arma-
mentarium. Now, with ArteFill, that vacancy in the toolbox
is ﬁlled. However, just as if one’s only tool is a hammer, all
the world becomes a nail, ArteFill is not a panacea. So far,
it has proved highly useful in creating long-lasting results
in a number of desirable applications. However, its true
versatility bears further exploration by those well-versed
and qualiﬁed in the art and science of aesthetic patient care.
ArteFill is an important tool and adjunct to many aes-
thetic treatments, but its potential transcends the aesthetic
niche. Difﬁcult reconstructive challenges associated with
contour deformities will no doubt beneﬁt from expanded
ArteFill indications. Many intractable medical problems,
such as urinary incontinence, gastroesophageal reﬂux dis-
ease (GERD), stress urinary incontinence (SUI), paralytic
vocal cord incompetence, and others may well beneﬁt from
this unique addition to the health care armamentarium.
Based on sound data supporting the safety and efﬁcacy of
ArteFill, the U.S. FDA approved it for the treatment of
nasolabial folds. Physiologically and qualitatively, the
dermal-subdermal interface of the nasolabial fold is no
different than the other such planes where ArteFill may
satisfy augmentation requirements. However, efﬁcacy
(good result) is very different from safety (absence of
harm). The authors encourage careful and controlled use of
this new and permanent ﬁller material. The safety record of
ArteFill so far is stellar. Concerns regarding ‘‘permanent
ﬁller, permanent problems’’ have not proved substantive.
As with any new product, there exist naysayers, some of
whom may have hidden agendas. Ultimately, it is sound
data that will drive honest discussion and sound decisions.
Five-year U.S. safety trials are presently in progress.
Disclosure Drs. G. Lemperle and S. Lemperle are the developers of
ArteFill
 . Dr. N. Sadick is a clinical investigator of ArteFill. None of
the authors has shares in any company that manufactures dermal ﬁller.
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